Literature DB >> 2605465

Ten-year review of non-ruptured aortic aneurysms.

P Mutirangura1, P A Stonebridge, A E Clason, J H McClure, J A Wildsmith, B Nolan, C V Ruckley, A M Jenkins.   

Abstract

Between 1978 and 1987, 587 cases of abdominal aortic aneurysm were operated on in the Vascular Unit of the Royal Infirmary of Edinburgh. Over this ten-year period there was a dramatic increase in the number of patients treated. Rupture had occurred in 278 patients. Of the 309 patients with non-ruptured aneurysm 175 were asymptomatic, 84 were symptomatic and 50 were acutely symptomatic. Two hundred and fifty-nine patients underwent elective operation and the 50 acutely symptomatic patients were operated on as emergencies. The overall mortality for the non-ruptured series was 2.9 per cent. The mortality in patients undergoing elective surgery was 1.9 per cent (1.1 per cent in asymptomatic and 3.6 per cent in symptomatic patients) and 4.0 per cent for patients undergoing emergency surgery.

Entities:  

Mesh:

Year:  1989        PMID: 2605465     DOI: 10.1002/bjs.1800761208

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  4 in total

1.  Small bowel function after aortic surgery.

Authors:  S G Barker; R D Dodds; A Middlemiss; C E Bennett; M H Russell; B C Sellick; M H Thomas
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

2.  Abdominal aortic aneurysms: the importance of elective repair.

Authors:  A F Horgan; D S O'Riordain; M P Brady; J A O'Donnell
Journal:  Ir J Med Sci       Date:  1991-01       Impact factor: 1.568

3.  Advantages of using the midline incision right retroperitoneal approach for abdominal aortic aneurysm repair.

Authors:  M Endo; K Kobayashi; M Tsubota; M Seki; H Sato; T Noto; T Iwa
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

4.  Informed consent: a case for more education of the surgical team.

Authors:  B Soin; W A Smellie; H J Thomson
Journal:  Ann R Coll Surg Engl       Date:  1993-01       Impact factor: 1.891

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.